Heart Failure

If patients attend their discharge appointments at pharmacist-led heart failure transition of care clinics, they are less likely to be readmitted to the hospital within 30 days.

With the release of the 2022 AHA/ACC Guidelines for the Management of Heart Failure, patients with HFpEF now have a wider range of treatment options.

Approximately half of patients with heart failure do not require an implantable monitoring device or do not qualify for thoracic monitoring.

A prespecified analysis of the DELIVER trial found the SGLT2 inhibitor dapagliflozin to benefit patients in a patient population previously excluded from heart failure outcomes trials.

Pharmacists need to ensure anticoagulants are held appropriately before and after surgery to prevent complications from for CIED infections.

The protein, called suPAR, has long been known to be a biomarker for poor outcomes and disease progression in both kidney disease and cardiovascular disease.

The American Heart Association said that yoga, tai-chi, and certain alternative medicines may be beneficial for heart failure, whereas other products may be harmful.

Study finds men are more likely to be prescribed statins and women are more likely to be advised to make lifestyle changes to lessen the risk of cardiovascular disease.

Nearly half of the study population received a first-time hypertension diagnosis post hospitalization, with approximately half of these new cases occurring more than 6 weeks postpartum.

Study does not show a statistically significant association for specific cardiovascular outcomes related to cardiac arrest or arrhythmias, cerebrovascular diseases, or myocardial infarction associated with medications for attention-deficit hyperactivity disorder.

Patients with difficult-to-control hypertension have greater risk of heart attack, stroke, end-stage renal disease, and heart failure.

Dapagliflozin is the first SGLT2 inhibitor approved by the FDA for treatment of patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

The Elecsys NT-proBNP test is an objective biomarker that aids in the diagnosis of individuals believed to have congestive heart failure.

In 2020, heart disease death rates increased in adults across all age, sex, racial and ethnic groups, specifically among younger adults and non-Hispanic Black adults.

However, findings do not preclude the possibility that mechanisms other than cardiac remodeling may be responsible for benefits of SGLT2 inhibition.

Intravenous iron reduced the risk of hospitalization for heart failure or cardiovascular death by approximately 20%.

Experts said the results will likely not alter practice and clinicians will likely continue to use torsemide.

Among heart failure patients, those who were at risk of social isolation had a worse attitude about advance care planning.

The results showed that these participants were more than 27 times as likely to develop VTE, more than 21.5 times as likely to be diagnosed with heart failure, and 17.5 times as likely to have a stroke.

Food insecurity has previously been linked to adverse cardiovascular outcomes, but research is limited regarding the local food environment and the association with death from heart failure.

Black adults are suggested to have an increased risk of heart failure, which highlights the need for equitable treatment and decision-making.

Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.

Furosemide injection 80 mg/10 mL (Furoscix; scPharmaceuticals) is indicated for the at-home treatment of congestion caused by fluid overload in adult patients with New York Heart Association Class II/III chronic heart failure.

The combination of loop diuretics with other drugs that act at different pharmacologic targets has been shown to improve diuretic response in patients with heart failure.

New research suggests that acetazolamide and standard loop-diuretic therapy may decrease congestion and prevent future hospitalizations in patients with acute decompensated heart failure.

High intake of refined grains linked to an increased risk of premature coronary artery disease.

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

The incremental use of drug combinations could prevent hospitalizations from heart failure among those who have higher ejection farction, a subgroup that struggles with insufficient data on treatments.

Researchers found that patients diagnosed with early-onset type 2 diabetes have a greater risk of premature death than the general population.

Pre-specified pooled analysis from phase 3 trials demonstrates 14% reduction in CV mortality and from any cause by 10% in individuals with HF, irrespective of ejection fraction.